- Clinical Interests
- Huntington's disease
- Alzheimer's disease
- Medical Education
- MD, University of Chicago Pritzker School of Medicine
- Residency, Massachusetts General Hospital
- Board Certifications
- Foreign Languages
- Boston: Massachusetts General Hospital
- Patient Gateway
- Yes, learn more
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - New York
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Research Summary
- Dr. Rosas and her team have focused primarily on the development of biomarkers for use in the study of neurodegenerative diseases, to better characterize progression, to better understand genotype/phenotype correlations, and to apply novel neuroimaging approaches in clinical trials with the overall aim of making them more efficient. We have begun to develop models that may explain clinically heterogeneous phenotypes and variability in disease progression. The current models for both disease prediction and prediction of disease progression are insensitive and inaccurate. We are planning to expand our efforts to include multi-modal and multi-spectral imaging approaches that promise both more precise measurements and made provide novel and important information on the neural underpinnings of HD and their clinical consequences.
Rosas HD, Zaleta AK, Lee SY, Pappu V, Salat DH, Hersch SM (2008) Complexity and heterogeneity: The role of the cortex in the clinical expression of HDN Brain Apr 131: 1057-68.
Rosas HD, LeeSY, Bender AC, Zaleta AK, Vange lM, Yu P, Fisch lB, Pappu V, Onorato C, Cha JH,Salat DH,Hersch S. Altered white matter microstructure in the corpus callosum in Huntingto's disease: implications for cortical disconnection. (2010) NeuroImage.49; 2995-3.
SalatDH, ChenJJ, vander Kouwe AJ, GreveDN, FischlB, Rosas HD.Hippocampal degeneration is associated with temporal and limbic gray/white matter tissue contrast in Alzheimer's disease.(2011)NeuroImage; 54,1795-802.
Rosas HD, Reuter M, Doros G, LeeS Y, TriggsTT, MalarickK ,Fischl B,Salat DH, Hersch SM. A Tale of Two Factors: What better determines rate of progression in HD, age or CAG repeat(2010) Movement Disorders.
First Huntington disease prevention trial shows treatment safety, suggests slowing of presymptomatic progression
The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging provided evidence that creatine might slow the progression of presymptomatic disease.
15 Parkman Street
Boston, MA 02114-3117
Phone 1: 617-726-5532
Phone 2: 617-726-1728